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sensitive inflammatory responses. These proteins trans-
port LPS from micelles to the cell surface by a two-
step mechanism. LBP first catalyzes the transfer of LPS
monomers from micelles to a binding site on sCD14,
and in a second step, LPS monomers are transferred
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from LPS±sCD14 complexes to the plasma membrane
of cells (Hailman et al., 1994; Wurfel et al., 1995; HailmanSummary
et al., 1996; Vasselon et al., 1997). While LBP and CD14
have been proposed as pattern recognition receptorsLipopolysaccharide ([LPS], an endotoxin) from most
for LPS (Pugin et al., 1994), recent studies show thatbacterial species provokes a strong inflammatory
LBP transfers not only LPS but also phospholipids, andresponse in naive animals. LPS from Rhodobacter
mCD14 binds not only LPS but also phospholipids (Yu etsphaeroides (RsLPS) has a relatively small hydropho-
al., 1997). Neither protein therefore exhibits the bindingbic region and does not stimulate cells or animals but
specificity needed to discriminate host from microbe.instead acts as antagonist of LPS action. Here, we
Further confirmation of this point comes from studiesshow that the activity of RsLPS is transformed from
of LPS antagonists. Noting that a particular LPS analogantagonist to full agonist by the addition of chlor-
known as Lipid IVA is an antagonist in human cells but anpromazine (CPZ) and other cationic membrane-active
agonist in murine cells, Delude et al. (1995) transfectedagents. In addition, while LPS is rapidly transported
human and murine cells with murine and human CD14from the plasma membrane to an intracellular site, we
and found that recognition of Lipid IVA as agonist orfind that RsLPS is not transported but instead remains
antagonist depended on the species of the cell, notin the cell periphery. Addition of CPZ also reverses
the species of the CD14. It is thus clear that patternthis behavior, causing RsLPS to be transported to a
recognition is not mediated by CD14 but by the cellsperinuclear site. The data suggest that the interaction
themselves.of LPS with membrane lipids is influenced by mem-
Vesicular traffic sorts both proteins and lipids intobrane-modifying agents such as CPZ, and these inter-
distinct compartments in cells, and we explored theactions dictate both its intracellular transport and its
possibility that vesicular transport may also serve inability to stimulate cellular responses.
discrimination of host from microbial lipids. We pre-
viously observed that introduction of fluorescent LPSIntroduction
monomers into the plasma membranes of leukocytes is
followed by rapid transport of LPS to an intracellularThe adaptive immune system employs clonal selection
site (Detmers et al., 1996). This transport is absent inof unique binding proteins (immunoglobulins or T cell
peritoneal macrophages from mice with a genetic defi-receptors) to provide specific recognition of pathogens.
ciency in responsiveness to LPS (Thieblemont andIn contrast, the mechanismsby which the innate immune
Wright, 1997), and agents such as wortmannin, a PI3Ksystem distinguishes pathogen from host are less well
inhibitor that interrupts this traffic, block cellular re-understood and remain a central question in immunol-
sponses to LPS (Detmers et al., 1996).ogy (Fearon and Locksley, 1996). The striking inflamma-
Here, we show that cells sort agonist and antagonisttory response to lipopolysaccharide (LPS) provides per-
LPS molecules differently. Biologically active LPS ishaps the best-studied example of innate recognition.
transported from the plasma membrane to a definedThe Lipid A region of LPS (Figure 1) is the portion of the
intracellular site while antagonist LPS (RsLPS) remainsLPS molecule recognized by eukaryotic cells and is well
at the cell periphery. We further show that addition ofconserved among bacterial species. The ability of LPS
cationic membrane-active agents enables cells to trans-to stimulate cells is lost following chemical alterations
port antagonist LPS toan intracellularsite and that thesein any of several portions of Lipid A (Rietschel et al.,
agents transform RsLPS from antagonist to agonist. Our1994), suggesting that several aspects of the LPS mole-
data confirm the role of lipid traffic in responses to LPScule contribute to recognition. Of particular note, removal
and suggest that both lipid traffic and biological re-of the hydrophobic chains esterified to the 3-hydroxy
sponses are dictated by the packing geometry of lipidsfatty acids results in a molecule that not only has lost
in the plasma membrane.inflammatory activity but which acts as an LPS antago-
nist (Kovach et al., 1990; Lynn and Golenbock, 1992).
Antagonist activity is also seen in a naturally occurring Results and Discussion
molecule (RsLPS, see Figures 1 and 3) which, like deac-
ylated LPS, has a reduced complement of hydrocarbon Cells Fail to Transport RsLPS
chains (Qureshi et al., 1988; Christ et al., 1994). to an Intracellular Site
Recent work has described two extracellular proteins, To determine if the cellular transport machinery discrimi-
LBP and CD14, that bind LPS and are necessary for nates between inflammatory and noninflammatory lip-
ids, we employed a fluorescent derivative of RsLPS
(BODIPY±RsLPS) and followed its uptake into PMN.*To whom correspondence should be addressed (e-mail: samuel_
wright@merck.com). In keeping with previous studies on LPS antagonists
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Figure 1. Molecular Structure of Salmonella
Minnesota and Rhodobacter Sphaeroides
Lipid A and Chlorpromazine
See text for further details.
(Kitchens et al., 1992; Kitchens and Munford, 1995), not shown). In contrast with biologically active fluores-
cent LPS, which is rapidly transported to a distinct intra-BODIPY±RsLPS was taken up by PMN (Figure 2A), and
this uptake was blocked by anti-CD14 antibodies (data cellular site (Detmers et al., 1996; Thieblemont and
Wright, 1997; see Figure 3C), the BODIPY±RsLPS was
not transported from the plasma membrane and re-
mained on the cell periphery. Similar observations were
made both in PMN (Figure 2A) and monocytes (data not
shown). These studies suggest that LPS antagonists
fail to be transported by the same mechanism as do
agonists. It should be noted that our confocal images
do not discriminate between LPS in plasma membrane
and small vesicles closely associated with the plasma
membrane. Our observation thus does not define the
precise step in lipid transport that is blocked by RsLPS.
RsLPS Blocks Transport of LPS
Additional experiments demonstrated that RsLPS not
only fails to be transported but also imposes a blockade
on transport of agonist LPS. Unlabeled RsLPS was
added to PMN with fluorescently labeled active LPS
(BODIPY±LPS). While BODIPY±LPS alone was trans-
ported to single or multiple punctate intracellular sites
in 30 min (Figure 3C), addition of equimolar RsLPS
caused the fluorescence to be restricted to the cell pe-
rimeter. Similar observations were made using both
PMN (Figure 3C) and monocytes (data not shown). To
determine if this blockade of transport correlated with
antagonism of functional responses, RsLPS was added
with an optimal dose of LPS in assays of both IL-6
production by peripheral blood leukocytes (Figure 3A)
and adhesion of PMN (data not shown). RsLPS blocked
both responses by z50 % when an amount equimolar
to the LPS was added and completely blocked IL-6
production by PBMC when 50-fold excess RsLPS was
added (Figure 3A). Therefore, concentrations of RsLPS
that antagonized the action of LPS also blocked trans-
port of LPS from the plasma membrane to an intracellu-
lar site.
Figure 2. Cellular Distribution of BODIPY±RsLPS in Human Neutro-
phils in the Absence or Presence of CPZ Restoration of the Endocytic Movement
(A) Representative cells exposed to BODIPY±RsLPS±sCD14 com- of RsLPS in the Presence of CPZ
plexes (100 ng/ml LPS, 30 min exposure). The ring fluorescence A simple interpretation of the above results derives from
suggests that the RsLPS remains at or near the plasma membrane. considerations of the hydrophile±lipophile balance of the
(B) 0.5 mM CPZ was added with the BODIPY±RsLPS. CPZ induced
two lipids. LPS is a cone-shaped lipid with a relativelythe transport and concentration of the BODIPY±RsLPS from the cell
large hydrophobic and a small hydrophilic region, causingperiphery to intracellular sites. Images represent individual optical
sections. Results are representative of three separate experiments. pure dispersions to pack in a nonlamellar cubic fashion
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Biological Responses Induced by RsLPS
in the Presence of CPZ
We sought to determine if the endocytic transport of
RsLPS driven by CPZ was sufficient for cell activation.
Indeed, addition of CPZ enabled RsLPS to cause a
strong induction of IL-6 in monocytes (Figure 4A), while
no cytokine production was detected in the presence
of CPZ or RsLPS alone. The strongest response was
observed at concentrations of CPZ in the range of 0.05
to 0.5 mM (Figure 4B) and was as great as that in re-
sponse to optimal concentrations of agonist LPS. The
ability to transform RsLPS from antagonist to agonist is
not restricted to CPZ, since other cationic amphipaths
including perphenazine, fluphenazine, thioridazine, tri-
fluoperazine, and lidocaine were also active (Figure 4B).
These drugs acted not only on RsLPS but also on chro-
matographically pure Lipid A derived from RsLPS (RSLA,
Figure 4C). Like RsLPS, RSLA functions as an antagonist
(Figure 5), and addition of CPZ transforms RSLA into
an agonist (Figure 4C). Additional studies showed that
these results were not limited to monocytes, since simi-
lar results were obtained when PMN adhesion was used
as an alternative measure of biological responses (Fig-
ure 4D). LPS antagonists similar to RsLPS have been
proposed as treatments for endotoxic shock (Golen-
Figure 3. RsLPS Blocks Responses of PBMC and PMN to LPS and bock et al., 1991; Christ et al., 1995). However, since
Prevents Intracellular Transport of LPS the pharmacology of LPS antagonists may be inverted
(A) Human PBMC were incubated with LPS±sCD14complexes (1 ng/ by drugs in common use, they would have to be used
ml LPS) and variable concentrations of RsLPS±sCD14 complexes. with extreme caution.
After 5 hr at 378C, the production of IL-6 in the supernatants was In the course of these studies, we have observed that
measured by ELISA.
the ability of CPZ to induce a biological response in(B and C) Adherent PMN were incubated with BODIPY±LPS±sCD14
PBMC after stimulation with RSLA showed donor-to-complexes (50 ng/ml BODIPY±LPS) in the absence (C) or presence
donor variability, with some blood donors responding(B) of RsLPS±sCD14 (50 ng/ml RsLPS) for 30 min at 378C. Cells were
washed, and the distribution of fluorescent LPS was viewed with a strongly and others weakly. We have also noticed that
confocal laser scanning microscope. In four repeats, 81% (n 5 159) the concentration of CPZ needed for an optimal re-
of PMN showed the fluorescence restricted to the cell perimeter in sponse varied from donor to donor from 0.005 to 0.5
the presence of RsLPS±sCD14 and BODIPY±LPS±sCD14, while only
mM. In order to determine if the movement of RsLPS11% (n 5 150) of cells showed this pattern in the absence of RsLPS±
from the cellular perimeter to a perinuclear location wassCD14.
correlated with the cytokine responses of cells, we fol-
lowed both processes in parallel in three donors charac-
(Brandenburg et al., 1996; De Kruijff, 1997). In contrast, terized by a high, an intermediate, and a low ability to
LPS antagonists such as RsLPS have a hydrophile± respond to RSLA in the presence of CPZ. As shown in
lipophile balance that is inverted, with a much smaller Table 1, BODIPY±RsLPS was internalized in most of the
hydrophobe due to fewer and shorter acylchains (Figure monocytes from a high-responding donor. In contrast,
1). Agonist and antagonist LPS molecules may thus im- the fluorescent antagonist was mostly in the cell perime-
pose complementary packing defects in the outer leaflet ter in monocytes from a low responder to RsLPS and
of a bilayer. A similar explanation has been proposed CPZ. These results indicate that, although donors ex-
for the ability of detergents with large hydrophile and hibit variations in the intensity of responses, the internal-
small hydrophobe to pack in bilayers with phospholipids ization of Rhodobacter sphaeroides LPS correlated well
with opposite distribution of mass (Cullis et al., 1986). with cell stimulation.
To test this notion, PBMC and PMN were treated with The above data show that CPZ induced the rapid
chlorpromazine (CPZ), a membrane-active, antipsy- endocytic uptake of an LPS antagonist, causing it to
chotic drug with a bulky hydrophobe and a small hydro- resemble agonist LPS. Like LPS, CPZ is known to parti-
phile (see Figure 1). At concentrations up to 0.5 mM, tion into membranes (Sheetz and Singer, 1974), and the
CPZ did not affect cytokine production of monocytes positively charged hydrophilic portion of CPZ is likely
to LPS (Figure 4A) or the uptake of fluorescent LPS (data to interact with the negatively charged hydrophile of
not shown). However, CPZ induced the rapid endocytic RsLPS. Since CPZ has a bulky hydrophobe (Figure 1),
uptake of BODIPY±RsLPS into several well-defined it will contribute substantial hydrophobic bulk upon as-
spots in the cytoplasm (Figure 2B). This movement sociation with RsLPS. This increased hydrophobic bulk
closely resembled that of fluorescent agonist LPS in may cause the RsLPS to more closely resemble agonist
PMN (Detmers et al., 1996, and Figure 3C). CPZ thus LPS in the same way that the full complement of fatty
appears to restore the endocytic movement lost in acids in Escherichia coli LPS (an agonist) distinguish
it from deacylated LPS, an antagonist (Figure 1 andRsLPS.
Immunity
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Figure 4. Membrane-Active Agents Cause RsLPS To Behave As an Agonist
(A) PBMC were incubated with RsLPS±sCD14 complexes (10 ng/ml RsLPS) or LPS±sCD14 (10 ng/ml LPS) complexes in the presence of CPZ
(0.5 mM) for 5 hr at 378C, and the production of IL-6 in the samples was measured by ELISA.
(B) PBMC were incubated with LPS±sCD14 complexes with increasing concentrations of CPZ or with other membrane-active antipsychotic
or anesthetic drugs. Addition of these drugs alone to PBMC did not induce cytokine production, and no toxicity of CPZ was detected with
propidium iodide staining of cells below 100 mM. (C) PBMC were incubated with RSLA±sCD14 (1 ng/ml RSLA) or LPS±sCD14 (1 ng/ml LPS)
complexes in the presence of different concentration of CPZ, and IL-6 production was measured as in Figure 4A.
(D) To assess the biological activity of RsLPS on human PMN, PMN were stimulated with LPS±sCD14 or with RsLPS±sCD14 complexes with
various concentrations of CPZ or other antipsychotic or anesthetic drugs.
Somerville et al., 1997). These observations suggest that This suggestion is also consistent with the ability of
structurally diverse cone-shaped molecules such asboth vesicular transport and innate recognition of LPS
may depend on its packing geometry in the plasma ceramide (Joseph et al., 1994; Barber et al., 1995) and
the glycosphingolipids of Sphingomonas paucimobilismembrane bilayer.
(Krziwonet al., 1995) tostimulate cells in a fashion similar
to that of LPS.Do Cells Recognize LPS Monomers or the Properties
Our report strengthens the connection between innateof Membranes Modified by the Presence
of Cone-Shaped Lipids Such as LPS?
The precise means by which hydrophobic bulk contrib-
utes to both endocytosis and biological responses to
LPS is not clear at this time, but one may envision two
distinct mechanisms. In the first, LPS monomers could
be recognized by a stoichiometric lock-and-key binding
event that could, in turn, trigger endocytic movement
and cellular responses. As described in the Introduction,
molecules with appropriate binding specificity for LPS
have not been discovered. The present observation that
the necessary hydrophobic bulk of LPS can be contrib-
uted either by covalently attached fatty acids or by a
range of noncovalently associated molecules such as
CPZ argues against a stoichiometric interaction with a
stereospecific recognition protein. An alternative that
we hereby propose is that both vesicular transport and Figure 5. Chromatographed Pure Rhodobacter Sphaeroides Lipid
innate recognition of LPS may depend on its packing A (RSLA) Functions As an Antagonist
geometry in the plasma membrane bilayer. In this sce- IL-6 secretion was measured as described in Figure 3A after incuba-
nario, LPS is not recognized as a monomer but as part of tion of PBMC with graded doses of LPS in the presence of graded
doses of RSLA.an assembly of molecules with unique physical features.
Intracellular Transport and Innate Recognition of LPS
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Table 1. CPZ-Stimulated Endocytosis and Cytokine Synthesis Vary in Parallel from Donor to Donora
Intracellular Staining (%)b with IL-6 Production (ng/ml) in
BODIPY±RsLPS±sCD14 Response to RSLA±s CD14
2CPZ 1CPZd 2CPZc 1CPZd
Donor A 2.4 90.9 0.18 6 0.09 4.5 6 0.79
Donor B 1.6 52.7 0.0 6 0.05 1.7 6 0.34
Donor C 2.2 5.9 0.33 6 0.21 0.55 6 0.09
a Adherent cells from three donors were observed after staining with BODIPY±RsLPS±sCD14 complexes (50 ng/ml BODIPY±RsLPS) in the
absence or presence of CPZ. In a parallel experiment, synthesis of IL-6 was measured after stimulation of the PBMC with RSLA±sCD14
complexes (1 ng/ml RSLA) in the absence or presence of CPZ. Variation in maximal responses prohibited averaging results of separate
experiments. The three donors in this experiment were chosen to exhibit a range of responses.
b Intracellular staining was calculated by dividing the number of adherent PBMC exhibiting an intracellular staining by the total number of
cells (n 5 194±286).
c The IL-6 production of PBMC in the presence of RSLA±sCD14 without CPZ was similar to that in unstimulated cells (data not shown).
d In each experiment, several concentrations of CPZ were tested (5 nM to 0.5 mM), and results are shown for the concentration yielding an
optimal IL-6 response.
100 mg/ml sCD14 was made by incubating with 5 mg/ml LPS for 16recognition of LPS and intracellular lipid traffic (Detmers
hr at 378C. Previous work has shown that under these conditionset al., 1996; Thieblemont and Wright, 1997). Cells clearly
all of the LPS forms stoichiometric complexes with monomeric
recognize and sort lipids with subtle chemical differ- sCD14 and that these complexes efficiently stimulate cells and de-
ences, segregating sphingomyelin, for example, from liver LPS to the membrane (Hailman et al., 1996; Vasselon et al.,
the closely similar phosphatidyl choline (Van Meer, 1997).
1989). As with LPS, it appears that the colligative proper-
Cell Preparationties of these lipids (for example the capacity to form
Heparinized blood was obtained by venipuncture from humanlipid rafts with cholesterol) play a role in their subcellular
healthy volunteers, and PBMC and PMN were purified on Neutrophil
movement and their ability to participate in signaling Isolation Medium (Cardinal Associates Inc., SantaFe, NM) according
cascades (Simons and Ikonen, 1997). We speculate that to the manufacturer's directions. Cells were suspended in HAP
buffer (Dulbecco's PBS with 0.5 mg/ml HSA, 0.3 U/ml aprotinin, andsimilar types of lipid sorting might serve in innate recog-
3 mM glucose).nition of microbial products. The genes responsible for
lipid sorting are largely unknown, but recent work has
Measurement of IL-6 Secretion by PBMC
identified a novel gene product necessary for transport Human PBMC (1 3 106 cells/ml) were incubated with LPS from
of cholesterol out of lysosomes (Carstea et al., 1997; Salmonella minnesota R595 (LPS) and LPS from Rhodobacter
sphaeroides (RsLPS). Both RsLPS and LPS were added as 1:1 com-Loftus et al., 1997), and we have shown that the Lpsd
plexes with sCD14. After 5 hr at 378C, culture supernatants weregene is necessary for transport of LPS from the plasma
obtained by centrifuging for 5 min at 1300 rpm and were stored atmembrane to its intracellular site of accumulation (Thie-
2208C.
blemont and Wright, 1997). We suggest that genes in- Samples were assayed for the presence of IL-6 using a commer-
volved in pattern recognition of microbial lipids may be cially available human IL-6 ELISA kit (Central Laboratories of the
similar to or identical with those involved in intracellular Netherlands Red Cross Blood Transfusion Service, Amsterdam, The
Netherlands), modified for use with smaller volumes of reagentslipid transport.
and for detection of IL-6 with a fluorescent alkaline phosphatase
substrate as described (Kusunoki et al., 1995). Results are the meanExperimental Procedures
values of triplicate wells 6 SEM.
Reagents
Adhesion of PMN to FibrinogenDulbecco's PBS, aprotinin, chlorpromazine hydrochloride, fluphen-
To assess the biological activity of human neutrophils in responseazine dihydrochloride, lidocaine hydrochloride, trifluoperazine hy-
to an agonist, adhesion of PMN to fibrinogen-coated surfaces medi-drochloride, perphenazine, ifenprodil, and haloperidol were pur-
ated by the leukocyte integrin CD11b/CD18 was measured as de-
chased from Sigma Chemical Co. Thioridazine hydrochloride was
scribed previously (Hailman et al., 1996). In brief, 5 ml of freshly
purchased from Aldrich (Milwaukee, WI). HSA was purchased from isolated PMN (1 3 107 cells/ml) was fluorescently labeled with 5-(and
Centeon, Armour, and Berring Pharmaceutical Co. (Kankakee, IL). 6-) carboxyfluorescein diacetate succinimidyl ester (Molecular
LPS from Salmonella minnesota R595 (LPS) and LPS from Rhodo- Probes). Then, cells were added to a 72-well Terasaki plate pre-
bacter sphaeroides (RsLPS) were purchased from List Biological coated with fibrinogen. Agonists were diluted in HAP to 2-fold the
Laboratories (Campbell, CA). Chromatographically purified Lipid A concentrations indicated, and 5 ml was added to the plate already
from RsLPS (Qureshi et al., 1988) was a generous gift of Dr. N. containing the cells. After 25 min at 378C, adhesion of PMN to the
Qureshi (Madison, WI). Purity was checked by TLC (Qureshi et al., plate was quantitated. The fluorescence in each well was measured
1991), and only one heavily stained spot could be observed. Recom- using a Cytofluor 2300 as a way of quantitating the total number of
binant human sCD14 was purified from conditioned medium of cells per well. The plate was then washed, and fluorescence was
Schneider-2 insect cells transfected with cDNA-encoding human measured again. The percentage of adhesion was calculated as:
CD14. (fluorescence after washing/fluorescence before washing) 3100.
BODIPY±LPS was prepared from LPS from Salmonella minnesota Results are the mean values of triplicate wells 6 SEM.
using a BODIPY FL amine labeling kit (BODIPY±LPS; Molecular
Probes, Eugene, OR) as previously described (Yu and Wright, 1996). Biological Responses Induced by RsLPS
BODIPY±RsLPS was prepared in an identical fashion. in the Presence of Drugs
To deliver LPS as a monomer, we first formed complexes of the Human PBMC and PMN were incubated with preformed complexes
of RsLPS±sCD14 and in the presence of various concentrations ofBODIPY±LPS with sCD14. To prepare complexes of LPS±sCD14,
Immunity
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membrane-active agents (1.0 mM fluphenazine, 0.5 mM lidocaine, De Kruijff, B. (1997). Lipids beyond the bilayer. Nature 386, 129±130.
0.1 mM thioridazine, 1.0 mM trifluoperazine, 1.0 mM perphenazine, Delude, R.L., Savedra, R., Zhao, H., Thieringer, R., Yamamoto, S.,
and 0.005 to 50 mM chlorpromazine). Cells were stimulated with Fenton, M.J., and Golenbock, D.T. (1995). CD14 enhances cellular
LPS±sCD14 complexes as a positive control. responses to endotoxin without imparting ligand-specific recogni-
A potential artifact in our studies might arise from the fact that tion. Proc. Natl. Acad. Sci. USA 92, 9288±9292.
perphenazine, fluphenazine, trifluoperazine, and chlorpromazine are Detmers, P.A., Thieblemont, N., Vasselon, T., Pironkova, R., Miller,
ligands for sigma receptors, and recent studies indicate that the D.S., and Wright, S.D. (1996). Potential role of membrane internaliza-
sigma receptor is an isoform of the yeast sterol C8-C7 isomerase tion and vesicle fusion in adhesion of neutrophils in response to
(Moebius et al., 1997). These antipsychotics may thus interfere with lipopolysaccharide and TNF. J. Immunol. 157, 5589±5596.
the last steps of cholesterol biosynthesis and may mediate changes
Fearon, D.T., and Locksley, R.M. (1996). The instructive role of innatein the membrane constitution. We have ruled out this possibility by
immunity in the acquired immune response. Science 272, 50±53.observing that haloperidol, which exhibits 140-fold greater sigma
Golenbock, D.T., Hampton, R.Y., Qureshi, N., Takayama, K., andbinding affinity than CPZ (de Costa and He, 1994), failed to induce
Raetz, C.R. (1991). Lipid A-like molecules that antagonize the effectsIL-6 production in the response of PBMC to RsLPS±sCD14 com-
of endotoxins on human monocytes. J. Biol. Chem. 266, 19490±plexes (data not shown). Similar results were obtained with the
19498.potent sigma binding activity ifenprodil. In addition, it is unlikely
Hailman, E., Lichenstein, H.S., Wurfel, M.M., Miller, D.S., Johnson,that cholesterol synthesis inhibition could affect plasma membrane
D.A., Kelley, M., Busse, L.A., Zukowski, M.M., and Wright, S.D.structure in the 30 min of our experiments with PMN.
(1994). Lipopolysaccharide (LPS)-binding protein accelerates the
binding of LPS to CD14. J. Exp. Med. 179, 269±277.Confocal Scanning Laser Microscopy
Hailman, E., Vasselon, T., Kelley, M., Busse, L.A., Hu, M.C.-T.,Purified PMN were washed in HAP buffer and plated on glass Mi-
Lichenstein, H.S., Detmers, P.A., and Wright, S.D. (1996). Stimulationcroslides (Carlson Scientific Inc., Peatone, IL) for 20 min on ice, then
of macrophages and neutrophils by complexes of lipopolysaccha-exposed to fluorescent LPS (100 ng/ml) for 30 min at 378C. The LPS
ride and soluble CD14. J. Immunol. 156, 4384±4390.and LPS analog were all added as complexes with sCD14. Following
the incubation, cells were washed in HAP and examined live by Joseph, C.K., Wright, S.D., Bornmann, W.G., Randolph, J.T., Kumar,
confocal microscopy. E.R., Bittman, R., Liu, J., and Kolesnick, R.N. (1994). Bacterial lipo-
Confocal scanner laser microscopy was performed using a Nikon polysaccharide has structural similarity to ceramide and stimulates
microscope equipped with a 3100 objective (NA 1.4) and Bio-Rad ceramide-activated protein kinase in myeloid cells. J. Biol. Chem.
MRC 600 instrumentation (Hercules, CA). Filters provided excitation 269, 17606±17610.
at 488 nm. Individual optical sections were collected digitally. The Kitchens, R.L., and Munford, R.S. (1995). Enzymatically deacylated
images were collected and analyzed through the software (Comos) lipopolysaccharide (LPS) can antagonize LPS at multiple sites in
of the confocal microscope (Bio-Rad). The figures display 1 mm the LPS recognition pathway. J. Biol. Chem. 270, 9904±9910.
optical sections taken approximately at the midpoint of the cells. Kitchens, R.L.,Ulevitch, R.J., and Munford, R.S. (1992). Lipopolysac-
charide (LPS) partial structures inhibit responses to LPS in a human
Acknowledgments macrophage cell line without inhibiting LPS uptake by a CD14-medi-
ated pathway. J. Exp. Med. 176, 485±494.
We wish to thank N. Qureshi for providing us with pure Lipid A Kovach, N.L., Yee, E., Munford, R.S., Raetz, C.R., and Harlan, J.M.
derived from RsLPS; T. Q. Cai, T. Park, and T. Vasselon for valuable (1990). Lipid IV A inhibits synthesis and release of tumor necrosis
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